LCTX

Lineage Cell Therapeutics Stock Analysis

AI Rating

Low
  • Quality4/10
  • Growth↓ 2/10
  • Value↓ 0/10
Lineage Cell Therapeutics sales and earnings growth
LCTX Growth
Fair
  • Revenue Y/Y↑ 53.24%
  • EPS Y/Y↓ -211.11%
  • FCF Y/Y↑ 17.82%
Lineage Cell Therapeutics gross and profit margin trends
LCTX Profitability
Neutral
  • Gross margin ↑ 99.00%
  • EPS margin↓ -436.50%
  • ROIC 5Y↓ 6822.28%
Lineage Cell Therapeutics net debt vs free cash flow
LCTX Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Lineage Cell Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗